Dalpiciclib

From WikiProjectMed
Jump to navigation Jump to search
Dalpiciclib
Clinical data
Other namesSHR-6390
Identifiers
  • 6-Acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
UNII
Chemical and physical data
FormulaC25H30N6O2
Molar mass446.555 g·mol−1

Dalpiciclib is a drug for the treatment of various forms of cancer.[1]

In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.[2]

Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.[3]

References

  1. ^ Chen X, Shen K (June 2023). "Dalpiciclib in advanced breast cancer". The Lancet. Oncology. 24 (6): 578–579. doi:10.1016/S1470-2045(23)00228-0. PMID 37269836.
  2. ^ "Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer". hengrui.com.
  3. ^ Sheikh MS, Satti SA (2021). "The emerging CDK4/6 inhibitor for breast cancer treatment". Molecular and Cellular Pharmacology. 13 (3): 9–12. PMC 8896653. PMID 35251463.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Dalpiciclib"